CTOs on the Move

T.J. Samson Community Hospital

www.tjsamson.org

 
T.J. Samson Community Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Glasgow, KY. To find more information about T.J. Samson Community Hospital, please visit www.tjsamson.org
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.tjsamson.org
  • 1301 N Race St
    Glasgow, KY USA 42141-3454
  • Phone: 270.651.4444

Executives

Name Title Contact Details

Similar Companies

ICANotes

ICANotes is a Asbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reimbursement Concepts

Reimbursement Concepts is a Weirton, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southern Oregon Orthopedics Inc

The physicians of Southern Oregon Orthopedics, Inc. have been providing the residents of Southern Oregon and Northern California with high quality orthopedic care for the past 50 years. Our physicians are active staff members at Rogue Valley Medical

ESTECH

ESTECH is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Ramon, CA. To find more information about ESTECH, please visit www.estech.com

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic